CLINICAL TRIALS, STUDIES, REGISTRIES, DATA

The DHMS initial aim was to improve the diagnosis, prevention and treatment of heart disease, over the years this has expanded to encompass metabolic diseases, such as fatty liver disease.  

The SpotCheck study will investigate the use of Nevisense as a point-of-care diagnostic tool to assist with skin cancer detection in a remote setting such as a non-specialist practice or pharmacy.

Earlier this year, FDA granted NEXUS™ Aortic Arch Stent Graft System as a breakthrough device.

The PATHFINDER I Registry is a pilot study to evaluate the safety and efficacy of the Auryon Atherectomy System in the real-world treatment of de novo, re-stenotic, and in-stent restenosis lesions in infrainguinal arteries of patients with Peripheral Artery Diseases.

MiR Scientific notes the data show that miR Scientific's platform can detect molecular evidence of prostate cancer with sensitivity of 94% and specificity of 92%, which translates to AUC of 0.98.

The AuroLase pivotal study follows the successful first-in-human pilot study that enrolled 46 subjects at three U.S. sites. Pandemic related delays to the one-year end of study biopsies for the final subset of feasibility study subjects should be resolved within the next several weeks and, consequently, final results of the feasibility study are expected later this year.

The study will evaluate the performance of the investigational TactiFlex™ Ablation Catheter, Sensor Enabled™ for people whose AFib symptoms are unable to be managed by medication.

"We are thrilled to have had a record number of MolecuLight-based clinical posters and presentations, from so many wound care professionals and settings, be included at the SAWC's Virtual Session", says Anil Amlani, MolecuLight's CEO.

LuViva will be studied to assess its ability to help detect a significant number of the up to 40% to 50% cases missed at the point of biopsy because of limitations in current imaging technology.